BERKELEY, Calif., and VANCOUVER, British Columbia, March 18, 2019 – BriaCell® Therapeutics Corp. (“BriaCell®” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces changes to its Board of Directors. BriaCell® is pleased to welcome the appointment of Dr. Rebecca Taub, M.D., and Mr. Vaughn C. …
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) — via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with BriaCell Therapeutics Corp. (BCTXF) (BCT.V), a client of NNW and immuno-oncology-focused biotechnology company developing targeted and …
BERKELEY, Calif., and VANCOUVER, British Columbia, February 26, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce a non-brokered private placement financing of 5,000,000 common shares of the Company at a price of C$0.10 per common share for …
· New insights into BriaDX™, BriaCell’s simple patient HLA-type identification test, will be presented at 2019 ASCO-SITC Clinical Immuno-Oncology Symposium held in in San Francisco, California, February 28-March 2, 2019. · Dr. Charles L. Wiseman will be a keynote speaker at Euro Breast Cancer Summit held in Paris, France, March 20-21, 2019. · Scientific findings …
BERKELEY, Calif., and VANCOUVER, British Columbia, February 12, 2019 – BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) (“BriaCell” or the “Company”), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces the appointment of Jamieson Bondarenko to the Company’s Board of Directors. Jamieson Bondarenko, CFA, CMT, is an active investor and provides strategic capital …
· Completed development of a novel frozen formulation of Bria-IMT™ for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs. · Upcoming attendance at Biotech Showcase in San Francisco, Jan. 7-9, 2019. · Abstract accepted by Keystone Symposia for presentation of advances in Bria-IMT™ and BriaDX™ programs, Jan. 20-24, 2019. …
· Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Initial efficacy data is expected in first quarter of 2019; · Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity with excellent safety and tolerability in advanced breast cancer patients. BERKELEY, Calif., and VANCOUVER, British Columbia, December …
Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018 · Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by …
· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) in advanced breast cancer. · Interim safety data of the combination study …
Phoenix, Nov. 6, 2018 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Dr. Bill Williams, BriaCell’s president and CEO, was recently interviewed by Everett Jolly of Stock Day. “BriaCell is developing the first off-the-shelf, personalized …